Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8.

Berenguer J, Lagerweij T, Zhao XW, Dusoswa S, van der Stoop P, Westerman B, de Gooijer MC, Zoetemelk M, Zomer A, Crommentuijn MHW, Wedekind LE, López-López À, Giovanazzi A, Bruch-Oms M, van der Meulen-Muileman IH, Reijmers RM, van Kuppevelt TH, García-Vallejo JJ, van Kooyk Y, Tannous BA, Wesseling P, Koppers-Lalic D, Vandertop WP, Noske DP, van Beusechem VW, van Rheenen J, Pegtel DM, van Tellingen O, Wurdinger T.

J Extracell Vesicles. 2018 Mar 13;7(1):1446660. doi: 10.1080/20013078.2018.1446660. eCollection 2018.

2.

High-Throughput Firefly Luciferase Reporter Assays.

Siebring-van Olst E, van Beusechem VW.

Methods Mol Biol. 2018;1755:19-29. doi: 10.1007/978-1-4939-7724-6_2.

PMID:
29671260
3.

Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck.

de Boer DV, Martens-de Kemp SR, Buijze M, Stigter-van Walsum M, Bloemena E, Dietrich R, Leemans CR, van Beusechem VW, Braakhuis BJM, Brakenhoff RH.

Oncotarget. 2017 May 16;8(58):97928-97940. doi: 10.18632/oncotarget.17880. eCollection 2017 Nov 17.

4.

A CDC42-centered signaling unit is a dominant positive regulator of endothelial integrity.

Amado-Azevedo J, Reinhard NR, van Bezu J, de Menezes RX, van Beusechem VW, van Nieuw Amerongen GP, van Hinsbergh VWM, Hordijk PL.

Sci Rep. 2017 Aug 31;7(1):10132. doi: 10.1038/s41598-017-10392-0.

5.

A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.

Siebring-van Olst E, Blijlevens M, de Menezes RX, van der Meulen-Muileman IH, Smit EF, van Beusechem VW.

Mol Oncol. 2017 May;11(5):534-551. doi: 10.1002/1878-0261.12052. Epub 2017 Apr 11.

6.

Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells.

Hodzic J, Sie D, Vermeulen A, van Beusechem VW.

Hum Gene Ther. 2017 Sep;28(9):766-780. doi: 10.1089/hum.2016.143. Epub 2017 Jan 23.

PMID:
28114818
7.

The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.

Martens-de Kemp SR, Brink A, van der Meulen IH, de Menezes RX, Te Beest DE, Leemans CR, van Beusechem VW, Braakhuis BJ, Brakenhoff RH.

Mol Cancer Ther. 2017 Mar;16(3):540-550. doi: 10.1158/1535-7163.MCT-16-0457. Epub 2016 Dec 15.

8.

miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110.

Bijnsdorp IV, Hodzic J, Lagerweij T, Westerman B, Krijgsman O, Broeke J, Verweij F, Nilsson RJ, Rozendaal L, van Beusechem VW, van Moorselaar JA, Wurdinger T, Geldof AA.

Oncotarget. 2016 Mar 29;7(13):16676-87. doi: 10.18632/oncotarget.7572.

9.

Sunitinib activates Axl signaling in renal cell cancer.

van der Mijn JC, Broxterman HJ, Knol JC, Piersma SR, De Haas RR, Dekker H, Pham TV, Van Beusechem VW, Halmos B, Mier JW, Jiménez CR, Verheul HM.

Int J Cancer. 2016 Jun 15;138(12):3002-10. doi: 10.1002/ijc.30022. Epub 2016 Mar 1.

10.

Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function.

de Lange J, Faramarz A, Oostra AB, de Menezes RX, van der Meulen IH, Rooimans MA, Rockx DA, Brakenhoff RH, van Beusechem VW, King RW, de Winter JP, Wolthuis RM.

Nat Commun. 2015 Oct 1;6:8399. doi: 10.1038/ncomms9399.

11.

Arming oncolytic viruses to leverage antitumor immunity.

de Gruijl TD, Janssen AB, van Beusechem VW.

Expert Opin Biol Ther. 2015 Jul;15(7):959-71. doi: 10.1517/14712598.2015.1044433. Epub 2015 May 10. Review.

PMID:
25959450
12.

A cell-based high-throughput screening assay for radiation susceptibility using automated cell counting.

Hodzic J, Dingjan I, Maas MJ, van der Meulen-Muileman IH, de Menezes RX, Heukelom S, Verheij M, Gerritsen WR, Geldof AA, van Triest B, van Beusechem VW.

Radiat Oncol. 2015 Feb 27;10:55. doi: 10.1186/s13014-015-0355-2.

13.

Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC.

Nagel R, Stigter-van Walsum M, Buijze M, van den Berg J, van der Meulen IH, Hodzic J, Piersma SR, Pham TV, Jiménez CR, van Beusechem VW, Brakenhoff RH.

Mol Cancer Ther. 2015 Jun;14(6):1434-44. doi: 10.1158/1535-7163.MCT-14-0846. Epub 2015 Mar 25.

14.

Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.

Belcaid Z, Lamfers ML, van Beusechem VW, Hoeben RC.

Hum Gene Ther. 2014 Oct;25(10):875-84. doi: 10.1089/hum.2014.092. Epub 2014 Sep 17. Review.

15.

Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress.

Kotov IN, Siebring-van Olst E, Knobel PA, van der Meulen-Muileman IH, Felley-Bosco E, van Beusechem VW, Smit EF, Stahel RA, Marti TM.

Mol Oncol. 2014 Dec;8(8):1747-59. doi: 10.1016/j.molonc.2014.07.008. Epub 2014 Jul 22.

16.

ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.

Dong W, van Ginkel JW, Au KY, Alemany R, Meulenberg JJ, van Beusechem VW.

Hum Gene Ther. 2014 Oct;25(10):897-904. doi: 10.1089/hum.2013.229. Epub 2014 Sep 17.

17.

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.

Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, van Geer MA, van Beusechem VW, Kaspers GJ, van Royen BJ, Jiménez CR, Helder MN.

Br J Cancer. 2013 Oct 15;109(8):2142-54. doi: 10.1038/bjc.2013.578. Epub 2013 Sep 24.

18.

Analysis of small-sample clinical genomics studies using multi-parameter shrinkage: application to high-throughput RNA interference screening.

van de Wiel MA, de Menezes RX, Siebring-van Olst E, van Beusechem VW.

BMC Med Genomics. 2013;6 Suppl 2:S1. doi: 10.1186/1755-8794-6-S2-S1. Epub 2013 May 7.

19.

Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.

Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ, Brakenhoff RH.

Clin Cancer Res. 2013 Apr 15;19(8):1994-2003. doi: 10.1158/1078-0432.CCR-12-2539. Epub 2013 Feb 26.

20.

Affordable luciferase reporter assay for cell-based high-throughput screening.

Siebring-van Olst E, Vermeulen C, de Menezes RX, Howell M, Smit EF, van Beusechem VW.

J Biomol Screen. 2013 Apr;18(4):453-61. doi: 10.1177/1087057112465184. Epub 2012 Oct 30.

PMID:
23112084
21.

Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.

Posthumadeboer J, van Egmond PW, Helder MN, de Menezes RX, Cleton-Jansen AM, Beliën JA, Verheul HM, van Royen BJ, Kaspers GJ, van Beusechem VW.

Oncotarget. 2012 Oct;3(10):1169-81.

22.

Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens.

Meliopoulos VA, Andersen LE, Birrer KF, Simpson KJ, Lowenthal JW, Bean AG, Stambas J, Stewart CR, Tompkins SM, van Beusechem VW, Fraser I, Mhlanga M, Barichievy S, Smith Q, Leake D, Karpilow J, Buck A, Jona G, Tripp RA.

FASEB J. 2012 Apr;26(4):1372-86. doi: 10.1096/fj.11-193466. Epub 2012 Jan 12. Review.

23.

Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain.

Idema S, Caretti V, Lamfers ML, van Beusechem VW, Noske DP, Vandertop WP, Dirven CM.

PLoS One. 2011;6(10):e24396. doi: 10.1371/journal.pone.0024396. Epub 2011 Oct 13.

24.

Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine.

Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tüting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD.

Cancer Res. 2011 Sep 1;71(17):5827-37. doi: 10.1158/0008-5472.CAN-11-0804. Epub 2011 Jul 11.

25.

WEE1 inhibition sensitizes osteosarcoma to radiotherapy.

PosthumaDeBoer J, Würdinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ, Kaspers GJ.

BMC Cancer. 2011 Apr 29;11:156. doi: 10.1186/1471-2407-11-156.

26.

Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Hangalapura BN, Oosterhoff D, Gupta T, de Groot J, Wijnands PG, van Beusechem VW, den Haan J, Tüting T, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD.

Vaccine. 2011 Mar 9;29(12):2313-21. doi: 10.1016/j.vaccine.2011.01.022. Epub 2011 Jan 25.

27.

Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions.

van Zeeburg HJ, Huizenga A, Brink A, van den Doel PB, Zhu ZB, McCormick F, Brakenhoff RH, van Beusechem VW.

Gene Ther. 2010 Dec;17(12):1517-24. doi: 10.1038/gt.2010.99. Epub 2010 Aug 5.

PMID:
20686507
28.

Objective determination of the oncolytic potency of conditionally-replicating adenoviruses using mathematical modeling.

Idema S, Dirven CM, van Beusechem VW, Carette JE, Planqué R, Noske DP, Lamfers ML, Vandertop WP.

J Gene Med. 2010 Jul;12(7):564-71. doi: 10.1002/jgm.1468.

PMID:
20603863
29.

Adenovirus retargeting to surface expressed antigens on oral mucosa.

van Zeeburg HJ, van Beusechem VW, Huizenga A, Haisma HJ, Korokhov N, Gibbs S, Leemans CR, Brakenhoff RH.

J Gene Med. 2010 Apr;12(4):365-76. doi: 10.1002/jgm.1447.

PMID:
20373331
30.

Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma.

Verheije MH, Lamfers ML, Würdinger T, Grinwis GC, Gerritsen WR, van Beusechem VW, Rottier PJ.

J Virol. 2009 Aug;83(15):7507-16. doi: 10.1128/JVI.00495-09. Epub 2009 May 13.

31.

Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice.

Schagen FH, Graat HC, Carette JE, Vellinga J, van Geer MA, Hoeben RC, Dermody TS, van Beusechem VW.

Hum Gene Ther. 2008 Aug;19(8):783-94. doi: 10.1089/hum.2007.133.

32.

Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases.

Graat HC, van Beusechem VW, Schagen FH, Witlox MA, Kleinerman ES, Helder MN, Gerritsen WR, Kaspers GJ, Wuisman PI.

Mol Cancer. 2008 Jan 23;7:9. doi: 10.1186/1476-4598-7-9.

33.

Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.

Lamfers ML, Idema S, Bosscher L, Heukelom S, Moeniralm S, van der Meulen-Muileman IH, Overmeer RM, van der Valk P, van Beusechem VW, Gerritsen WR, Vandertop WP, Dirven CM.

Clin Cancer Res. 2007 Dec 15;13(24):7451-8.

34.

AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy.

Idema S, Lamfers ML, van Beusechem VW, Noske DP, Heukelom S, Moeniralm S, Gerritsen WR, Vandertop WP, Dirven CM.

J Gene Med. 2007 Dec;9(12):1046-56.

PMID:
17966130
35.

Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53.

Graat HC, Carette JE, Schagen FH, Vassilev LT, Gerritsen WR, Kaspers GJ, Wuisman PI, van Beusechem VW.

Mol Cancer Ther. 2007 May;6(5):1552-61.

36.

A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.

Carette JE, Graat HC, Schagen FH, Mastenbroek DC, Rots MG, Haisma HJ, Groothuis GM, Schaap GR, Bras J, Kaspers GJ, Wuisman PI, Gerritsen WR, van Beusechem VW.

Virology. 2007 Apr 25;361(1):56-67. Epub 2006 Dec 19.

37.

Antibody-mediated targeting of viral vectors to the Fc receptor expressed on acute myeloid leukemia cells.

Würdinger T, Verheije MH, van der Aa LM, Bosch BJ, de Haan CA, van Beusechem VW, Gerritsen WR, Rottier PJ.

Leukemia. 2006 Dec;20(12):2182-4. Epub 2006 Oct 12. No abstract available.

PMID:
17039233
38.

Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.

Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weissleder R, Vandertop WP, van Beusechem VW, Dirven CM, Chiocca EA.

Mol Ther. 2006 Dec;14(6):779-88. Epub 2006 Sep 22.

39.

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.

Graat HC, Witlox MA, Schagen FH, Kaspers GJ, Helder MN, Bras J, Schaap GR, Gerritsen WR, Wuisman PI, van Beusechem VW.

Br J Cancer. 2006 Jun 19;94(12):1837-44. Epub 2006 May 30.

40.

Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein.

Schagen FH, Wensveen FM, Carette JE, Dermody TS, Gerritsen WR, van Beusechem VW.

Mol Ther. 2006 May;13(5):997-1005. Epub 2006 Mar 3.

41.

Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter.

Verheije MH, Würdinger T, van Beusechem VW, de Haan CA, Gerritsen WR, Rottier PJ.

J Virol. 2006 Feb;80(3):1250-60.

42.

Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.

Würdinger T, Verheije MH, Broen K, Bosch BJ, Haijema BJ, de Haan CA, van Beusechem VW, Gerritsen WR, Rottier PJ.

J Virol. 2005 Dec;79(24):15314-22.

43.

Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.

Lamfers ML, Gianni D, Tung CH, Idema S, Schagen FH, Carette JE, Quax PH, Van Beusechem VW, Vandertop WP, Dirven CM, Chiocca EA, Gerritsen WR.

Cancer Res. 2005 Oct 15;65(20):9398-405.

44.

Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer.

Heideman DA, Steenbergen RD, van der Torre J, Scheffner M, Alemany R, Gerritsen WR, Meijer CJ, Snijders PJ, van Beusechem VW.

Mol Ther. 2005 Dec;12(6):1083-90. Epub 2005 Aug 8.

45.
46.

Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy.

Heideman DA, Overmeer RM, van Beusechem VW, Lamers WH, Hakvoort TB, Snijders PJ, Craanen ME, Offerhaus GJ, Meijer CJ, Gerritsen WR.

Cancer Gene Ther. 2005 Dec;12(12):954-62.

PMID:
15905856
47.

Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody.

Würdinger T, Verheije MH, Raaben M, Bosch BJ, de Haan CA, van Beusechem VW, Rottier PJ, Gerritsen WR.

Gene Ther. 2005 Sep;12(18):1394-404.

PMID:
15843808
48.

Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses.

Graat HC, Wuisman PI, van Beusechem VW, Carette JE, Gerritsen WR, Bras J, Schaap GR, Kaspers GJ, Ogose A, Gu W, Kawashima H, Hotta T.

Clin Cancer Res. 2005 Mar 15;11(6):2445-7; author reply 2447-8. No abstract available.

49.

Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site.

Carette JE, Graat HC, Schagen FH, Abou El Hassan MA, Gerritsen WR, van Beusechem VW.

J Gene Med. 2005 Aug;7(8):1053-62.

PMID:
15756711
50.

Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.

Oosterhoff D, Overmeer RM, de Graaf M, van der Meulen IH, Giaccone G, van Beusechem VW, Haisma HJ, Pinedo HM, Gerritsen WR.

Br J Cancer. 2005 Mar 14;92(5):882-7.

Supplemental Content

Loading ...
Support Center